Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ANDAs For Drug/Device Combos Face High Bar At US FDA; Epipen, Advair May Benefit

Executive Summary

Generics must be able to be administered without provider intervention or patient retraining, draft guidance says.

You may also be interested in...



Stayin’ Alive: GSK Sees Options For Brand Advair In A Post-Generic World

Payers might be open to keeping the Advair brand on formulary even if a generic becomes available, because GSK has a portfolio of respiratory drugs to leverage in negotiations, CEO Andrew Witty said during the company’s third quarter conference call.

Complex ANDAs To Be Allowed Pre-Submission Product Meetings

FDA will be able to give scientific advice and sponsors can familiarize reviewers with upcoming generic applications for complex products under new provision in GDUFA II.

EpiPen Generics: Woodcock Explains Injector Studies

In response to Congressional questions about whether FDA is a barrier to competition for the epinephrine product, CDER Director lays out what could be required to prove an injector device problem is fixed.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB002431

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel